[Long-term therapy of cancer pain. A controlled study on buprenorphine].
Sublingual tablets of buprenorphine (Temgesic sublingual) were given in a controlled trial of 41 patients for 2804 patient-days. With a mean starting dose of 1.09 mg and a final dose of 1.53 mg buprenorphine daily there was a good pain-relieving effect. The interval between doses was six to eight hours. The trial did not reveal any direct pointers as to tolerance or addictiveness after long-term intake of the drug. Because of its effectiveness and good duration of action, as well as the absence of negative long-term effects, the drug can be recommended in the long-term management of cancer pain.
Zenz
M
M
Piepenbrock
S
S
Tryba
M
M
Glocke
M
M
Everlien
M
M
Klauke
W
W
D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D008134:Long-Term Care; D009019:Morphinans / Q000627:therapeutic use*; D009369:Neoplasms / Q000150:complications*; D010148:Intractable Pain / Q000188:drug therapy* / Q000209:etiology; D010166:Palliative Care
D009019:Morphinans; D002047:Buprenorphine
Langzeittherapie von Krebsschmerzen. Kontrollierte Studie mit Buprenorphin.